[{"address1": "2440 Research Boulevard", "address2": "Suite 400", "city": "Rockville", "state": "MD", "zip": "20850", "country": "United States", "phone": "240 745 6330", "website": "https://www.i-mabbiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Wei  Fu", "age": 42, "title": "Executive Chairman", "yearBorn": 1982, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Xi-Yong  Fu M.B.A., Ph.D.", "age": 52, "title": "CEO & Director", "yearBorn": 1972, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kyler  Lei", "title": "Chief Financial Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tyler  Ehler", "title": "Senior Director of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claire  Xu M.D., Ph.D.", "title": "Senior Vice President of Clinical Development", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Phillip  Dennis M.D., Ph.D.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Sean Wuxiong Cao M.B.A., Ph.D.", "title": "Chief Business Development Officer & Independent Director", "exercisedValue": 0, "unexercisedValue": 0}], "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 4.64, "open": 4.7, "dayLow": 4.49, "dayHigh": 4.7698, "regularMarketPreviousClose": 4.64, "regularMarketOpen": 4.7, "regularMarketDayLow": 4.49, "regularMarketDayHigh": 4.7698, "payoutRatio": 0.0, "beta": 1.458, "forwardPE": -3.1496599, "volume": 819571, "regularMarketVolume": 819571, "averageVolume": 2064590, "averageVolume10days": 1371740, "averageDailyVolume10Day": 1371740, "bid": 3.39, "ask": 5.76, "bidSize": 2, "askSize": 2, "marketCap": 533681856, "fiftyTwoWeekLow": 0.595, "fiftyTwoWeekHigh": 6.79, "allTimeHigh": 85.4, "allTimeLow": 0.595, "fiftyDayAverage": 4.4808, "twoHundredDayAverage": 2.3118, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 693759232, "profitMargins": 0.0, "floatShares": 97820014, "sharesOutstanding": 115266053, "sharesShort": 3654523, "sharesShortPriorMonth": 2177585, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.0317, "heldPercentInsiders": 0.21398, "heldPercentInstitutions": 0.21099001, "shortRatio": 2.01, "shortPercentOfFloat": 0.0397, "impliedSharesOutstanding": 82623296, "bookValue": 2.405, "priceToBook": 1.925156, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -39990000, "trailingEps": -0.51, "forwardEps": -1.47, "enterpriseToEbitda": -18.216, "52WeekChange": 3.5412846, "SandP52WeekChange": 0.19736934, "quoteType": "EQUITY", "currentPrice": 4.63, "targetHighPrice": 10.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.6, "targetMedianPrice": 9.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 5, "totalCash": 165614000, "totalCashPerShare": 0.88, "ebitda": -38085000, "totalDebt": 3481000, "quickRatio": 22.648, "currentRatio": 22.817, "debtToEquity": 1.769, "returnOnAssets": -0.10358, "returnOnEquity": -0.18456, "freeCashflow": -7126875, "operatingCashflow": 43591000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "IMAB", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "I-MAB", "longName": "NovaBridge Biosciences", "marketState": "CLOSED", "regularMarketPrice": 4.63, "corporateActions": [{"header": "Ticker Change", "message": "IMAB is trading under new symbol NBP effective Oct. 30, 2025", "meta": {"eventType": "TICKER_CHANGE", "dateEpochMs": 1761796800000, "newTicker": "NBP"}}], "regularMarketTime": 1761768001, "exchange": "NGM", "messageBoardId": "finmb_642067965", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -0.215512, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1579271400000, "regularMarketChange": -0.00999975, "regularMarketDayRange": "4.49 - 4.7698", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2064590, "fiftyTwoWeekLowChange": 4.035, "fiftyTwoWeekLowChangePercent": 6.7815123, "fiftyTwoWeekRange": "0.595 - 6.79", "fiftyTwoWeekHighChange": -2.1599998, "fiftyTwoWeekHighChangePercent": -0.31811485, "fiftyTwoWeekChangePercent": 354.12845, "earningsTimestamp": 1755144000, "earningsTimestampStart": 1762950600, "earningsTimestampEnd": 1762950600, "earningsCallTimestampStart": 1724846400, "earningsCallTimestampEnd": 1724846400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.51, "epsForward": -1.47, "epsCurrentYear": -0.31333, "priceEpsCurrentYear": -14.776753, "fiftyDayAverageChange": 0.14919996, "fiftyDayAverageChangePercent": 0.033297617, "twoHundredDayAverageChange": 2.3182, "twoHundredDayAverageChangePercent": 1.0027684, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "I-Mab", "nameChangeDate": "2025-10-31", "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "trailingPegRatio": null, "__fetch_time": "2025-11-01"}]